Hikma reiterates full year guidance following good start to the year
Riad Mishlawi, Hikma's CEO, said:
'We are pleased to reiterate our Group guidance for 2025. As a global company with strong local expertise and footprint, we are leveraging our manufacturing proficiency and advanced technologies to meet the needs of our customers and patients across our markets. Looking ahead, and recognising the broader geo-political challenges, we are well-positioned. Our step up in R&D investment, alongside local manufacturing enhancements, and strategic partnerships will continue to strengthen our portfolio and pipeline and ensure sustained success."
Injectables
Our global Injectables business is delivering a solid revenue performance, driven by each of our three geographies. We are seeing strong demand for our products across our European and MENA markets, where we continue to launch new products. In North America we are benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio. This is helping to offset increased competition across some of our existing higher margin products.
We expect momentum to improve in the second half driven by new product launches and contract manufacturing. We are making excellent progress in the enhancements to our Bedford, Ohio facility, which will significantly increase our US-based injectables manufacturing capacity.
We continue to expect 2025 Injectables revenue to grow in the range of 7% to 9%. Phasing and mix of sales will impact margins in the first half but we continue to expect full year core operating margin to be in the mid-30s.
Branded
Our Branded business is performing well. We continue to make good progress in building our diversified portfolio of products used to treat chronic illnesses, with a focus on oncology and lifestyle diseases, supported by our global expertise and strong local market position.
Our leading presence in the MENA region, combined with the breadth of our reach and strong commercial capabilities positions us as a partner of choice. We recently signed an exclusive licensing agreement with pharmaand GmbH, a global pharmaceutical business based in Vienna, to commercialise rucaparib, an innovative small-molecule oral oncology therapy, across the MENA region. This is in line with our strategy to be a leading provider of oncology medicines in the region.
We continue to expect 2025 Branded revenue to grow in the range of 6% to 7% in constant currency, with core EBIT margin close to 25%.
Generics
In our Generics business we are seeing solid demand across our differentiated portfolio, particularly for our nasal and inhalation products. By focusing on reliability of supply, high service levels and leveraging our US manufacturing facility, we are successfully securing longer-term customer awards.
We continue to strengthen our R&D capabilities, including building a team in our new Zagreb, Croatia R&D centre, and are progressing with key development projects that will help strengthen our portfolio and pipeline for the medium to long-term. We are progressing well preparing our Columbus facility to accommodate our recently announced contract manufacturing partnership, and we are seeing increasing demand for our high-quality US-based manufacturing services.
We continue to expect Generics revenue to be broadly flat in 2025 with core operating margin of around 16%.
International trade policies
We are confident that our significant and expanding US manufacturing footprint, which supplies the majority of our US sales, combined with our focus on quality and reliability of supply, positions us well and underpins our resilience in the current environment. We do import some finished products into the US as well as capital equipment, and we have a diversified global supply chain for our raw and packaging materials, including active pharmaceutical ingredients (API).
Full year outlook unchanged
We continue to expect Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $730 million to $770 million in 2025. Group core operating profit growth, which is around 4% at the midpoint of guidance, will be weighted to the second half. We are monitoring the evolving tariff backdrop and will look to remain agile in responding to both opportunities and impacts where possible, but have not reflected an impact from tariffs in our full year outlook.
About Hikma
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the MENA and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
*Source: AETOSWire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
3 hours ago
- Al Etihad
Stocks and dollar dip as Trump's spending bill passes, trade deal deadline nears
4 July 2025 15:21 LONDON (REUTERS)Stocks slipped on Friday as US President Donald Trump got his signature tax cut bill over the line and attention turned to his July 9 deadline for countries to secure trade deals with the world's biggest dollar also fell against major currencies with US markets already shut for the holiday-shortened week, as traders considered the impact of Trump's sweeping spending bill which is expected to add an estimated $3.4 trillion to the national pan-European STOXX 600 index fell 0.8%.US S&P 500 futures edged down 0.6%, following a 0.8% overnight advance for the cash index to a fresh all-time closing peak. Wall Street is closed on Friday for the Independence Day said Washington will start sending letters to countries on Friday specifying what tariff rates they will face on exports to the United States, a clear shift from earlier pledges to strike scores of individual deals before a July 9 deadline when tariffs could rise are "now just waiting for July 9," said Tony Sycamore, an analyst at IG, with the market's lack of optimism for trade deals responsible for some of the equity weakness in export-reliant Asia, particularly Japan and South the same time, investors cheered the surprisingly robust jobs report on Thursday, sending all three of the main US equity indexes climbing in a shortened session."The US economy is holding together better than most people expected, which suggests to me that markets can easily continue to do better (from here)," Sycamore the close, the House narrowly approved Trump's signature, 869-page bill, which averts the near-term prospect of a US government default but adds trillions to the national debt to fuel spending on border security and the military. Trade the Key Focus in Asia Trump said he expected "a couple" more trade agreements after announcing a deal with Vietnam on Wednesday to add to framework agreements with China and Britain as the only successes so Treasury Secretary Scott Bessent said earlier this week that a deal with India is close. However, progress on agreements with Japan and South Korea, once touted by the White House as likely to be among the earliest to be announced, appears to have broken US dollar index had its worst first half since 1973 as Trump's chaotic roll-out of sweeping tariffs heightened concerns about the US economy and the safety of Treasuries, but had rallied 0.4% on Thursday before retracing some of those gains on of 1100 GMT it was down 0.1% at euro added 0.2% to $1.1773, while sterling held steady at $ US Treasury bond market is closed on Friday for the holiday, but 10-year yields rose 4.7 basis points (bps) to 4.34%, while the 2-year yield jumped 9.3 bps to 3.882%.Gold firmed 0.4% to $3,336 per ounce, on track for a weekly gain as investors again sought refuge in safe-haven assets due to concerns over the US's fiscal position and tariffs. Brent crude futures fell 64 cents to $68.17 a barrel, while US West Texas Intermediate crude likewise dropped 64 cents to $66.35, as Iran reaffirmed its commitment to nuclear non-proliferation. Stock Markets Continue full coverage
TECHx
5 hours ago
- TECHx
UiPath Names David Popovici Global Ambassador
Home » Tech Value Chain » Global Brands » UiPath Names David Popovici Global Ambassador UiPath, agentic automation, has announced Romanian Olympic swimming champion David Popovici as its new Global Ambassador. The company revealed that Popovici will attend and speak at several UiPath events worldwide. The four-year partnership will support his preparation for major European and international swimming competitions, including the 2028 Summer Olympic Games in Los Angeles. David Popovici, a freestyle specialist born in Bucharest, gained global attention at the 2022 World Championships. At just 17, he became the first male swimmer in 49 years to win both the 100m and 200m freestyle events at the same championship. He also became the second-youngest swimmer to win the men's 200m world title. In the same year, Popovici won gold in both freestyle events at the European Championships. He broke the 100m freestyle world record and set a new junior record in the 200m. In 2024, Popovici improved on his fourth-place finish from the 2021 Tokyo Olympics. He won gold in the 200m freestyle and bronze in the 100m at the Paris 2024 Olympic Games. Currently, he is training for his third consecutive Olympics and will next compete at the Singapore 2025 World Aquatics Championships. UiPath Co-Founder and CEO Daniel Dines commented on the partnership, saying it reflects the synergy between human excellence and technological innovation. 'What makes David a champion isn't just raw talent it's his ability to bring together every element that drives excellence,' Dines stated. He compared Popovici's precision, discipline, and perseverance to UiPath's vision of integrating people, AI agents, and robots through agentic orchestration. Popovici also shared his thoughts on the collaboration. He highlighted UiPath's commitment to innovation and global impact. 'UiPath is a place where innovative ideas are supported,' said Popovici. 'It feels natural to partner with a strong brand that has stayed true to its roots.' The company also announced that between September 29 and October 1, 2025, it will host the first edition of UiPath FUSION, a high-tech event for the global UiPath community. Popovici will join CEO Daniel Dines on stage at the event. Key highlights: Popovici will represent UiPath at global events for four years. He aims to compete in the 2028 Olympics and 2025 World Aquatics Championships. UiPath continues to align its brand with top global talent to showcase its values of innovation, discipline, and excellence. Image Source: Wikipedia
Khaleej Times
5 hours ago
- Khaleej Times
Dubai temporarily closes Ras Al Khor sanctuary for Dh650-million development
The contract for the first phase was awarded, and it will be completed by the end of next year.
